Share this article
Share this article
PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed an exclusive Supply, Distribution and Services Agreement with Daavlin. Securing long-term supply and distribution of a commercially ready light device is an integral component of the regulatory and commercial strategy for SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL).
Daavlin has a 40-year history of innovation and development in the field of phototherapy, providing an extensive line of products and services to health care providers and patients worldwide for the purposes of treating photoresponsive skin disorders such as psoriasis, vitiligo and now CTCL. The company s corporate headquarters and manufacturing plant
RESEARCH TRIANGLE PARK –United Therapeutics, which has a big operation in RTP, is paying $105 million to acquire a voucher that it says will accelerate its New Drug Application process with the FDA.
The Maryland-based company (Nasdaq: UTHR) announced the deal for the so-called Priority Review Voucher early Monday. It did not disclose the selling party for the voucher.
In the first half of 2021, United plans to submit a NDA for Tyvaso which it describres as “an investigational drug-device combination product comprised of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.” Treatment targets are “pulmonary arterial hypertension (PAH), as well as pulmonary hypertension associated with interstitial lung disease (PH-ILD),” the company says.
A transcript of the presentation will be archived for 30 days following the event.
About Oral Mucositis
Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. per year and occurs in 40% of patients receiving chemotherapy. Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition and narcotic analgesia. The gastrointestinal damage causes severe diarrhea. These symptoms can limit the doses and duration of cancer treatment, leading to sub-optimal treatment outcomes.